A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3084077 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs LY 3084077 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 29 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2013 Planned End Date changed from 1 Feb 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 30 Oct 2013 Planned End Date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.